{"id":829446,"date":"2025-03-25T08:47:06","date_gmt":"2025-03-25T12:47:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/"},"modified":"2025-03-25T08:47:06","modified_gmt":"2025-03-25T12:47:06","slug":"genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/","title":{"rendered":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease"},"content":{"rendered":"
\n

– U.S. Food and Drug Administration states that data from the ongoing OnPrime\/GOG-3076 Phase 3 registrational trial could potentially support traditional approval –<\/em><\/p>\n

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Genelux Corporation<\/a> (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that\u00a0Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant\/refractory ovarian cancer (PRROC).<\/p>\n

Currently, Olvi-Vec is being evaluated in the OnPrime\/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival (Clinicaltrials.gov identifier NCT05281471<\/a>). The purpose of the FDA meeting was to discuss the FDA\u2019s expectations with respect to the requirements necessary for the granting of traditional approval of Olvi-Vec.<\/p>\n

In response to a question seeking the FDA\u2019s guidance on their expectations regarding a confirmatory trial using the ongoing OnPrime\/GOG-3076 trial, the FDA responded that \u201cAs stated previously, an interim analysis of overall survival (OS) should be planned at the time of the primary PFS analysis. If a clinically meaningful PFS advantage is demonstrated in the absence of a decrement in OS, this could potentially support traditional approval.\u201d The FDA further recommended Genelux request a pre-BLA meeting with FDA with topline safety and efficacy data following completion of the study to discuss next steps.<\/p>\n

\u201cWe appreciate the feedback from the FDA regarding our clinical strategy for OnPrime\/GOG-3076 and the plan for submission of an eventual marketing application, which could avoid the need for conducting a separate confirmatory study if the clinically meaningful PFS advantage is demonstrated,\u201d stated Thomas Zindrick, President and CEO. \u201cThe FDA\u2019s guidance regarding their expectations for the ongoing trial represents a significant milestone as we look forward to reporting topline safety and efficacy data in the first half of 2026. We remain committed to advancing a therapeutic option with the potential to provide a significant benefit for individuals living with PRROC, whose critical unmet need for innovative treatments is urgent.\u201d<\/p>\n

\n About the OnPrime\/GOG-3076 Trial<\/strong>
\n
OnPrime\/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician’s choice of chemotherapy and bevacizumab in patients with PRROC. The trial is enrolling patients who are platinum resistant\/refractory by standard definitions and received a minimum of 3 prior lines of therapy. The experimental arm patients receive a single cycle (two doses) of Olvi-Vec administered intraperitoneally and, approximately four weeks later, a regimen of a platinum-based doublet plus bevacizumab followed by maintenance therapy. The active comparator arm patients receive a regimen of single agent chemotherapy with optional platinum, plus bevacizumab followed by maintenance therapy. The trial will enroll a sufficient number of patients to achieve 127 events, with the primary endpoint of progression free survival and with secondary endpoints including overall survival.<\/p>\n

The trial is designed to address a broad and underserved pool of ovarian cancer patients with no approved standard of care therapies. The inclusion criteria allows patients to enroll regardless of (i) tumor biomarkers, (ii) platinum refractory tumors or (iii) the maximum number of prior lines of treatments (i.e., no cap on previous treatments).<\/p>\n

\n About Olvi-Vec<\/strong>
\n
Olvi-Vec (olvimulogene nanivacirepvec), Genelux\u2019s most advanced product candidate is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity.\u00a0Genelux\u00a0is developing Olvi-Vec for the treatment of multiple types of cancer based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types\u00a0in vitro<\/em>\u00a0and\u00a0in vivo<\/em>\u00a0and produce an anti-tumor immune response. Genelux granted Newsoara an exclusive license to develop and commercialize Olvi-Vec in greater China (i.e., Mainland China, Hong Kong, Macau and Taiwan). To date, Olvi-Vec has been administered to more than 150 patients in seven completed clinical trials. In these trials, Olvi-Vec was observed to be generally well tolerated with data demonstrating clinical benefit. Olvi-Vec has been granted Fast Track designation by the US FDA for the treatment of platinum resistant\/refractory ovarian cancer.<\/p>\n

\n About Genelux Corporation<\/strong>
\n
Genelux\u00a0is a late-stage clinical biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and\/or difficult-to-treat solid tumor types. In addition to OnPrime\/GOG-3076, Olvi-Vec currently is being evaluated in two clinical studies designed to demonstrated the ability to induce platinum resensitization via systemic administration: VIRO-25, a U.S.-based multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet + physician’s choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer and in Olvi-Vec-SCLC-202, a Phase 1b\/2, open-label, China-based multicenter clinical trial evaluating the safety, tolerability, pharmacokinetics and efficacy of intravenously delivered Olvi-Vec combined with platinum and etoposide in the treatment of platinum-relapsed or platinum-refractory extensive small cell lung cancer patients. The core of\u00a0Genelux’s\u00a0discovery and development efforts revolves around its proprietary CHOICE\u2122 platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.<\/p>\n

\n Forward-Looking Statements
<\/strong>This release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. \u201cForward-looking statements\u201d describe future expectations, plans, results, or strategies and are generally preceded by words such as \u201cbelieves,\u201d \u201canticipates,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cplan\u201d or \u201cwill\u201d. Forward-looking statements in this release include, but are not limited to, the potential regulatory approval pathway; the submission of a marketing application; capabilities, advantages, safety and efficacy of Olvi-Vec to treat platinum resistant\/refractory ovarian cancer; and the Company\u2019s expectations regarding the timing and availability of data. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption \u201cRisk Factors\u201d in Genelux\u2019s filings with the\u00a0Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management\u2019s assumptions and estimates as of such date.\u00a0Genelux\u00a0does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.<\/p>\n

\n Investor and Media Contacts<\/strong>
\n
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com<\/p>\n

Source: Genelux Corporation<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

– U.S. Food and Drug Administration states that data from the ongoing OnPrime\/GOG-3076 Phase 3 registrational trial could potentially support traditional approval – WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that\u00a0Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant\/refractory ovarian cancer (PRROC). Currently, Olvi-Vec is being evaluated in the OnPrime\/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival (Clinicaltrials.gov identifier NCT05281471). The purpose of the FDA meeting was to discuss the FDA\u2019s expectations with respect to the requirements necessary for the granting of traditional … <\/p>\n

Continue reading “Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829446","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGenelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– U.S. Food and Drug Administration states that data from the ongoing OnPrime\/GOG-3076 Phase 3 registrational trial could potentially support traditional approval – WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that\u00a0Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant\/refractory ovarian cancer (PRROC). Currently, Olvi-Vec is being evaluated in the OnPrime\/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival (Clinicaltrials.gov identifier NCT05281471). The purpose of the FDA meeting was to discuss the FDA\u2019s expectations with respect to the requirements necessary for the granting of traditional … Continue reading "Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T12:47:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\\\/Refractory Disease\",\"datePublished\":\"2025-03-25T12:47:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/\"},\"wordCount\":1105,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/\",\"name\":\"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\\\/Refractory Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=\",\"datePublished\":\"2025-03-25T12:47:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\\\/Refractory Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/","og_locale":"en_US","og_type":"article","og_title":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease - Market Newsdesk","og_description":"– U.S. Food and Drug Administration states that data from the ongoing OnPrime\/GOG-3076 Phase 3 registrational trial could potentially support traditional approval – WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that\u00a0Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant\/refractory ovarian cancer (PRROC). Currently, Olvi-Vec is being evaluated in the OnPrime\/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival (Clinicaltrials.gov identifier NCT05281471). The purpose of the FDA meeting was to discuss the FDA\u2019s expectations with respect to the requirements necessary for the granting of traditional … Continue reading \"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T12:47:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease","datePublished":"2025-03-25T12:47:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/"},"wordCount":1105,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/","name":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=","datePublished":"2025-03-25T12:47:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDE3MSM2ODMyMzIzIzIyNDkwNTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genelux-announces-alignment-with-fda-on-key-elements-of-the-approval-pathway-for-olvi-vec-in-platinum-resistant-refractory-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant\/Refractory Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829446"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829446\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}